XORTXABOUTPIPELINESTRATEGIC PARTNERSHIPSINVESTORSCONTACTCORONAVIRUS XORTX Therapeutics Inc. is a biopharmaceutical company with three products in clinical development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-221, under a letter of intent to establish a co-development program with Teijin Pharma Limited, for Type 2 Diabetic

Nephropathy (T2DN).

PIPELINE – XORTXUPCOMING EVENTSLEGAL DISCLAIMERADVISORY BOARDFINANCIALSDIABETIC NEPHROPATHYSEDAR XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com

INVESTORS – XORTX

XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com XORTX ANNOUNCES PRIVATE PLACEMENT NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. CALGARY, Alberta, Jan. 07, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces a non-brokered private XORTX WELCOMES NEW MEMBER TO BOARD OF DIRECTORS XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com RECENT PRESS RELEASES Advancing Partner and Investor Outreach Activities CALGARY, Alberta, March 01, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces its participation in the WuXI Healthcare Forum to be held virtually March 15-18, XORTXABOUTPIPELINESTRATEGIC PARTNERSHIPSINVESTORSCONTACTCORONAVIRUS XORTX Therapeutics Inc. is a biopharmaceutical company with three products in clinical development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-221, under a letter of intent to establish a co-development program with Teijin Pharma Limited, for Type 2 Diabetic

Nephropathy (T2DN).

PIPELINE – XORTXUPCOMING EVENTSLEGAL DISCLAIMERADVISORY BOARDFINANCIALSDIABETIC NEPHROPATHYSEDAR XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com

INVESTORS – XORTX

XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com XORTX ANNOUNCES PRIVATE PLACEMENT NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. CALGARY, Alberta, Jan. 07, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces a non-brokered private XORTX WELCOMES NEW MEMBER TO BOARD OF DIRECTORS XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com RECENT PRESS RELEASES Advancing Partner and Investor Outreach Activities CALGARY, Alberta, March 01, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces its participation in the WuXI Healthcare Forum to be held virtually March 15-18, XORTX WELCOMES NEW MEMBER TO BOARD OF DIRECTORS XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com XORTX CLOSES OVER SUBSCRIBED PRIVATE PLACEMENT CALGARY, Alberta, Feb. 10, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that it has closed the over-subscribed private placement, initially announced on January 7, 2021, for total gross proceeds of

CORONAVIRUS

The Company is actively reviewing current studies characterizing the outbreak of COVID-19. The company believes that these published reports may clearly illustrate that acute kidney injury and acute pulmonary injury are key factors in the most serious cases of COVID-19 hospitalization and death. STRATEGIC PARTNERSHIPS Strategic partnerships are an integral part of our corporate strategy. XORTX Therapeutics is working with development and commercialization partners in garnering new approvals, launching products and developing products that meet the needs of both patients and physicians. XORTX CONFIRMS $1 MILLION IN WARRANT EXERCISE PROCEEDS XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a common life-threatening genetic diseases, affecting many individuals in all parts of the world. ADPKD is a progressive kidney and cardiovas

BOARD OF DIRECTORS

XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com XORTX ANNOUNCES CHANGE TO BOARD OF DIRECTORS XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com

2018 PRESS RELEASES

Shorter Path to XRx-008 Marketing Approval CALGARY, Alberta, Oct. 23, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease (“PKD”), is pleased to announce that the Company’s clinical development plan has been reviewed and APAC RESOURCES INC. AND XORTX PHARMA CORP. ANNOUNCE Vancouver, BC – January 10, 2018 – APAC Resources Inc. (“APAC”) (CSE:APG:CNX) and XORTX Pharma Corp. (“XORTX”) are pleased to announce the completion of the previously announced reverse take-over and acquisition by APAC of all of the issued and outstanding shares (“XORTX Shares”) of XORTX (the “Acquisition”).The resulting company, XORTX Therapeutics Inc. (“XRX” or the XORTXABOUTPIPELINESTRATEGIC PARTNERSHIPSINVESTORSCONTACTCORONAVIRUS XORTX Therapeutics Inc. is a biopharmaceutical company with three products in clinical development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-221, under a letter of intent to establish a co-development program with Teijin Pharma Limited, for Type 2 Diabetic

Nephropathy (T2DN).

PIPELINE – XORTXUPCOMING EVENTSLEGAL DISCLAIMERADVISORY BOARDFINANCIALSDIABETIC NEPHROPATHYSEDAR Pipeline. XORTX Therapeutics Inc. is a biopharmaceutical company with three products in clinical development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-221 for Type 2 Diabetic Nephropathy (T2DN). The Company has intellectual property rights and established proof of

INVESTORS – XORTX

XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com RECENT PRESS RELEASES Advancing Partner and Investor Outreach Activities CALGARY, Alberta, March 01, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces its participation in the WuXI Healthcare Forum to be held virtually March 15-18, XORTX WELCOMES NEW MEMBER TO BOARD OF DIRECTORS XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com XORTX ANNOUNCES PRIVATE PLACEMENT NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. CALGARY, Alberta, Jan. 07, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces a non-brokered private XORTX CONFIRMS $1 MILLION IN WARRANT EXERCISE PROCEEDS XORTX Confirms $1 Million in Warrant Exercise Proceeds. March 2, 2021. by aaronbb. CALGARY, Alberta, March 02, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased XORTX CLOSES OVER SUBSCRIBED PRIVATE PLACEMENT XORTX Closes Over Subscribed Private Placement. February 10, 2021. by aaronbb. CALGARY, Alberta, Feb. 10, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased

to

DIABETIC NEPHROPATHY Diabetic nephropathy (DN) is a progressive kidney disease caused by thickening of the capillaries in the kidney glomeruli. People with both types I and type II diabetes are at risk. The risk is higher if blood-glucose levels are poorly controlled. Furthermore, once nephropathy develops, the greatest rate of progression is seen in

patients with

A LEADER REDEFINING HOW KIDNEY DISEASE IS TREATED INVESTOR 2 Forward Looking Statements This document contains forward-looking information pursuant to applicable securities law. All information that addresses activities or developments that XORTX expects to occur in the future are forward-looking statements. XORTXABOUTPIPELINESTRATEGIC PARTNERSHIPSINVESTORSCONTACTCORONAVIRUS XORTX Therapeutics Inc. is a biopharmaceutical company with three products in clinical development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-221, under a letter of intent to establish a co-development program with Teijin Pharma Limited, for Type 2 Diabetic

Nephropathy (T2DN).

PIPELINE – XORTXUPCOMING EVENTSLEGAL DISCLAIMERADVISORY BOARDFINANCIALSDIABETIC NEPHROPATHYSEDAR Pipeline. XORTX Therapeutics Inc. is a biopharmaceutical company with three products in clinical development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-221 for Type 2 Diabetic Nephropathy (T2DN). The Company has intellectual property rights and established proof of

INVESTORS – XORTX

XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com RECENT PRESS RELEASES Advancing Partner and Investor Outreach Activities CALGARY, Alberta, March 01, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces its participation in the WuXI Healthcare Forum to be held virtually March 15-18, XORTX WELCOMES NEW MEMBER TO BOARD OF DIRECTORS XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com XORTX ANNOUNCES PRIVATE PLACEMENT NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. CALGARY, Alberta, Jan. 07, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces a non-brokered private XORTX CONFIRMS $1 MILLION IN WARRANT EXERCISE PROCEEDS XORTX Confirms $1 Million in Warrant Exercise Proceeds. March 2, 2021. by aaronbb. CALGARY, Alberta, March 02, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased XORTX CLOSES OVER SUBSCRIBED PRIVATE PLACEMENT XORTX Closes Over Subscribed Private Placement. February 10, 2021. by aaronbb. CALGARY, Alberta, Feb. 10, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased

to

DIABETIC NEPHROPATHY Diabetic nephropathy (DN) is a progressive kidney disease caused by thickening of the capillaries in the kidney glomeruli. People with both types I and type II diabetes are at risk. The risk is higher if blood-glucose levels are poorly controlled. Furthermore, once nephropathy develops, the greatest rate of progression is seen in

patients with

A LEADER REDEFINING HOW KIDNEY DISEASE IS TREATED INVESTOR 2 Forward Looking Statements This document contains forward-looking information pursuant to applicable securities law. All information that addresses activities or developments that XORTX expects to occur in the future are forward-looking statements. XORTX WELCOMES NEW MEMBER TO BOARD OF DIRECTORS XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com

CORONAVIRUS

XORTX has filed a patent application for XRx-101 targeted at the treatment of respiratory and kidney disease due to viral infection. COVID-19 is a serious viral infection due to a coronavirus. Coronavirus infections such as SARS and MERS and specifically COVID-19 can be frequently accompanied by pneumonia, acute kidney injury,

proteinuria and

XORTX CLOSES OVER SUBSCRIBED PRIVATE PLACEMENT CALGARY, Alberta, Feb. 10, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that it has closed the over-subscribed private placement, initially announced on January 7, 2021, for total gross proceeds of XORTX CONFIRMS $1 MILLION IN WARRANT EXERCISE PROCEEDS XORTX Confirms $1 Million in Warrant Exercise Proceeds. March 2, 2021. by aaronbb. CALGARY, Alberta, March 02, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased XORTX ANNOUNCES CHANGE TO BOARD OF DIRECTORS XORTX Announces Change to Board of Directors. August 28, 2020 December 22, 2020. by aaronbb. CALGARY, Alberta, Aug. 28, 2020 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (CSE : XRX) (OTCQB : XRTXF) (FRANKFURT : ANU1) (the “Company” or “XORTX”) a late clinical stage pharmaceutical development company focused on kidney disease, is

pleased

STRATEGIC PARTNERSHIPS Strategic partnerships are an integral part of our corporate strategy. XORTX Therapeutics is working with development and commercialization partners in garnering new approvals, launching products and developing products that meet the needs of both patients and physicians. RECENT PRESS RELEASES NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. CALGARY, Alberta, March 02, 2020 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that it has

BOARD OF DIRECTORS

Board of Directors. Bruce Rowlands. Chairman. Bruce Rowlands has held the position of Chairman since May 2018 and a director of XORTX Pharma Corp., the Company’s predecessor since 2014. Bruce is the former Chairman and CEO of Eurocontrol Technics Group Inc., a TSX Venture Exchange listed company. Prior to forming Eurocontrol, Bruce worked in XORTX ANNOUNCES FIRST TRANCHE CLOSING OF NON-BROKERED CALGARY, Alberta, March 02, 2020 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that it has closed a first tranche of the non-brokered

private placement

AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a common life-threatening genetic diseases, affecting many individuals in all parts of the world. ADPKD is a progressive kidney and cardiovascular disease. Cardiovascular disease is the leading cause of premature mortality in patients with ADPKD, with over 80% of deaths attributable

to

XORTXABOUTPIPELINESTRATEGIC PARTNERSHIPSINVESTORSCONTACTCORONAVIRUS XORTX Therapeutics Inc. is a biopharmaceutical company with three products in clinical development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-221, under a letter of intent to establish a co-development program with Teijin Pharma Limited, for Type 2 Diabetic

Nephropathy (T2DN).

PIPELINE – XORTXUPCOMING EVENTSLEGAL DISCLAIMERADVISORY BOARDFINANCIALSDIABETIC NEPHROPATHYSEDAR XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com

INVESTORS – XORTX

XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com RECENT PRESS RELEASES Advancing Partner and Investor Outreach Activities CALGARY, Alberta, March 01, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces its participation in the WuXI Healthcare Forum to be held virtually March 15-18, XORTX WELCOMES NEW MEMBER TO BOARD OF DIRECTORS XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com XORTX ANNOUNCES PRIVATE PLACEMENT NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. CALGARY, Alberta, Jan. 07, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces a non-brokered private XORTX CLOSES OVER SUBSCRIBED PRIVATE PLACEMENT CALGARY, Alberta, Feb. 10, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that it has closed the over-subscribed private placement, initially announced on January 7, 2021, for total gross proceeds of

MANAGEMENT TEAM

Dr. Allen W. Davidoff, phd CEO Dr. Allen Davidoff (15 years drug development experience) is the founder and CEO of XORTX. Allen has a broad range of clinical and regulatory experience and senior management experience in pharmaceutical R&D including two investigational new drug (“IND”) applications or supplemental IND’s, two phase I studies (four of which were multi-country), seven

phase

ADVISORY BOARD

XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com A LEADER REDEFINING HOW KIDNEY DISEASE IS TREATED INVESTOR 2 Forward Looking Statements This document contains forward-looking information pursuant to applicable securities law. All information that addresses activities or developments that XORTX expects to occur in the future are forward-looking statements. XORTXABOUTPIPELINESTRATEGIC PARTNERSHIPSINVESTORSCONTACTCORONAVIRUS XORTX Therapeutics Inc. is a biopharmaceutical company with three products in clinical development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-221, under a letter of intent to establish a co-development program with Teijin Pharma Limited, for Type 2 Diabetic

Nephropathy (T2DN).

PIPELINE – XORTXUPCOMING EVENTSLEGAL DISCLAIMERADVISORY BOARDFINANCIALSDIABETIC NEPHROPATHYSEDAR XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com

INVESTORS – XORTX

XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com RECENT PRESS RELEASES Advancing Partner and Investor Outreach Activities CALGARY, Alberta, March 01, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces its participation in the WuXI Healthcare Forum to be held virtually March 15-18, XORTX WELCOMES NEW MEMBER TO BOARD OF DIRECTORS XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com XORTX ANNOUNCES PRIVATE PLACEMENT NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. CALGARY, Alberta, Jan. 07, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces a non-brokered private XORTX CLOSES OVER SUBSCRIBED PRIVATE PLACEMENT CALGARY, Alberta, Feb. 10, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that it has closed the over-subscribed private placement, initially announced on January 7, 2021, for total gross proceeds of

MANAGEMENT TEAM

Dr. Allen W. Davidoff, phd CEO Dr. Allen Davidoff (15 years drug development experience) is the founder and CEO of XORTX. Allen has a broad range of clinical and regulatory experience and senior management experience in pharmaceutical R&D including two investigational new drug (“IND”) applications or supplemental IND’s, two phase I studies (four of which were multi-country), seven

phase

ADVISORY BOARD

XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com A LEADER REDEFINING HOW KIDNEY DISEASE IS TREATED INVESTOR 2 Forward Looking Statements This document contains forward-looking information pursuant to applicable securities law. All information that addresses activities or developments that XORTX expects to occur in the future are forward-looking statements.

INVESTORS – XORTX

XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com

CORONAVIRUS

The Company is actively reviewing current studies characterizing the outbreak of COVID-19. The company believes that these published reports may clearly illustrate that acute kidney injury and acute pulmonary injury are key factors in the most serious cases of COVID-19 hospitalization and death. XORTX CLOSES OVER SUBSCRIBED PRIVATE PLACEMENT CALGARY, Alberta, Feb. 10, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that it has closed the over-subscribed private placement, initially announced on January 7, 2021, for total gross proceeds of XORTX CONFIRMS $1 MILLION IN WARRANT EXERCISE PROCEEDS XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com

MANAGEMENT TEAM

Dr. Allen W. Davidoff, phd CEO Dr. Allen Davidoff (15 years drug development experience) is the founder and CEO of XORTX. Allen has a broad range of clinical and regulatory experience and senior management experience in pharmaceutical R&D including two investigational new drug (“IND”) applications or supplemental IND’s, two phase I studies (four of which were multi-country), seven

phase

STRATEGIC PARTNERSHIPS Strategic partnerships are an integral part of our corporate strategy. XORTX Therapeutics is working with development and commercialization partners in garnering new approvals, launching products and developing products that meet the needs of both patients and physicians. DIABETIC NEPHROPATHY XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com XORTX ANNOUNCES INCREASE TO PRIVATE PLACEMENT XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com

BOARD OF DIRECTORS

XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a common life-threatening genetic diseases, affecting many individuals in all parts of the world. ADPKD is a progressive kidney and cardiovas XORTXABOUTPIPELINESTRATEGIC PARTNERSHIPSINVESTORSCONTACTCORONAVIRUS XORTX Therapeutics Inc. is a biopharmaceutical company with three products in clinical development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-221, under a letter of intent to establish a co-development program with Teijin Pharma Limited, for Type 2 Diabetic

Nephropathy (T2DN).

PIPELINE – XORTXUPCOMING EVENTSLEGAL DISCLAIMERADVISORY BOARDFINANCIALSDIABETIC NEPHROPATHYSEDAR Pipeline. XORTX Therapeutics Inc. is a biopharmaceutical company with three products in clinical development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-221 for Type 2 Diabetic Nephropathy (T2DN). The Company has intellectual property rights and established proof of RECENT PRESS RELEASES Advancing Partner and Investor Outreach Activities CALGARY, Alberta, March 01, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces its participation in the WuXI Healthcare Forum to be held virtually March 15-18,

CORONAVIRUS

XORTX has filed a patent application for XRx-101 targeted at the treatment of respiratory and kidney disease due to viral infection. COVID-19 is a serious viral infection due to a coronavirus. Coronavirus infections such as SARS and MERS and specifically COVID-19 can be frequently accompanied by pneumonia, acute kidney injury,

proteinuria and

XORTX ANNOUNCES PRIVATE PLACEMENT NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. CALGARY, Alberta, Jan. 07, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces a non-brokered private

MANAGEMENT TEAM

Management Team. Dr. Allen Davidoff (15 years drug development experience) is the founder and CEO of XORTX. Allen has a broad range of clinical and regulatory experience and senior management experience in pharmaceutical R&D including two investigational new drug (“IND”) applications or supplemental IND’s, two phase I studies

(four of

ADVISORY BOARD

XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com DIABETIC NEPHROPATHY Diabetic nephropathy (DN) is a progressive kidney disease caused by thickening of the capillaries in the kidney glomeruli. People with both types I and type II diabetes are at risk. The risk is higher if blood-glucose levels are poorly controlled. Furthermore, once nephropathy develops, the greatest rate of progression is seen in

patients with

REDEFINING HOW KIDNEY DISEASE IS TREATED Our multi-tiered patent portfolio is composed of grantedpatents and patent applications that claim the “use of uric acid lowering agents” for the treatment of hypertension, insulin resistance and diabetic nephropathy (DN) (granted) and acute injury due to A LEADER REDEFINING HOW KIDNEY DISEASE IS TREATED INVESTOR 2 Forward Looking Statements This document contains forward-looking information pursuant to applicable securities law. All information that addresses activities or developments that XORTX expects to occur in the future are forward-looking statements. XORTXABOUTPIPELINESTRATEGIC PARTNERSHIPSINVESTORSCONTACTCORONAVIRUS XORTX Therapeutics Inc. is a biopharmaceutical company with three products in clinical development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-221, under a letter of intent to establish a co-development program with Teijin Pharma Limited, for Type 2 Diabetic

Nephropathy (T2DN).

PIPELINE – XORTXUPCOMING EVENTSLEGAL DISCLAIMERADVISORY BOARDFINANCIALSDIABETIC NEPHROPATHYSEDAR Pipeline. XORTX Therapeutics Inc. is a biopharmaceutical company with three products in clinical development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-221 for Type 2 Diabetic Nephropathy (T2DN). The Company has intellectual property rights and established proof of RECENT PRESS RELEASES Advancing Partner and Investor Outreach Activities CALGARY, Alberta, March 01, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces its participation in the WuXI Healthcare Forum to be held virtually March 15-18,

CORONAVIRUS

XORTX has filed a patent application for XRx-101 targeted at the treatment of respiratory and kidney disease due to viral infection. COVID-19 is a serious viral infection due to a coronavirus. Coronavirus infections such as SARS and MERS and specifically COVID-19 can be frequently accompanied by pneumonia, acute kidney injury,

proteinuria and

XORTX ANNOUNCES PRIVATE PLACEMENT NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. CALGARY, Alberta, Jan. 07, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces a non-brokered private

MANAGEMENT TEAM

Management Team. Dr. Allen Davidoff (15 years drug development experience) is the founder and CEO of XORTX. Allen has a broad range of clinical and regulatory experience and senior management experience in pharmaceutical R&D including two investigational new drug (“IND”) applications or supplemental IND’s, two phase I studies

(four of

ADVISORY BOARD

XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com DIABETIC NEPHROPATHY Diabetic nephropathy (DN) is a progressive kidney disease caused by thickening of the capillaries in the kidney glomeruli. People with both types I and type II diabetes are at risk. The risk is higher if blood-glucose levels are poorly controlled. Furthermore, once nephropathy develops, the greatest rate of progression is seen in

patients with

REDEFINING HOW KIDNEY DISEASE IS TREATED Our multi-tiered patent portfolio is composed of grantedpatents and patent applications that claim the “use of uric acid lowering agents” for the treatment of hypertension, insulin resistance and diabetic nephropathy (DN) (granted) and acute injury due to A LEADER REDEFINING HOW KIDNEY DISEASE IS TREATED INVESTOR 2 Forward Looking Statements This document contains forward-looking information pursuant to applicable securities law. All information that addresses activities or developments that XORTX expects to occur in the future are forward-looking statements.

CORONAVIRUS

XORTX has filed a patent application for XRx-101 targeted at the treatment of respiratory and kidney disease due to viral infection. COVID-19 is a serious viral infection due to a coronavirus. Coronavirus infections such as SARS and MERS and specifically COVID-19 can be frequently accompanied by pneumonia, acute kidney injury,

proteinuria and

INVESTORS – XORTX

XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com XORTX WELCOMES NEW MEMBER TO BOARD OF DIRECTORS XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com

ABOUT US – XORTX

About Us. XORTX Therapeutics Inc (XORTX) is a drug development company primarily focused on orphan disease indications which have a uric acid imbalance as well as metabolic syndrome, diabetes and diabetic nephropathy. XORTX possesses patents and patent applications that may include US and international rights regarding the development of uric XORTX ANNOUNCES PRIVATE PLACEMENT NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. CALGARY, Alberta, Jan. 07, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces a XORTX CLOSES OVER SUBSCRIBED PRIVATE PLACEMENT CALGARY, Alberta, Feb. 10, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that it has closed the over-subscribed private placement, initially announced on January 7, 2021, for total gross proceeds of STRATEGIC PARTNERSHIPS Strategic partnerships are an integral part of our corporate strategy. XORTX Therapeutics is working with development and commercialization partners in garnering new approvals, launching products and developing products that meet the needs of both patients and physicians.

BOARD OF DIRECTORS

Board of Directors. Bruce Rowlands. Chairman. Bruce Rowlands has held the position of Chairman since May 2018 and a director of XORTX Pharma Corp., the Company’s predecessor since 2014. Bruce is the former Chairman and CEO of Eurocontrol Technics Group Inc., a TSX Venture Exchange listed company. Prior to forming Eurocontrol, Bruce worked in DIABETIC NEPHROPATHY Diabetic nephropathy (DN) is a progressive kidney disease caused by thickening of the capillaries in the kidney glomeruli. People with both types I and type II diabetes are at risk. The risk is higher if blood-glucose levels are poorly controlled. Furthermore, once nephropathy develops, the greatest rate of progression is seen in

patients with

AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a common life-threatening genetic diseases, affecting many individuals in all parts of the world. ADPKD is a progressive kidney and cardiovascular disease. Cardiovascular disease is the leading cause of premature mortality in patients with ADPKD, with over 80% of deaths attributable

to

XORTXABOUTPIPELINESTRATEGIC PARTNERSHIPSINVESTORSCONTACTCORONAVIRUS XORTX Therapeutics Inc. is a biopharmaceutical company with three products in clinical development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-221, under a letter of intent to establish a co-development program with Teijin Pharma Limited, for Type 2 Diabetic

Nephropathy (T2DN).

PIPELINE – XORTXUPCOMING EVENTSLEGAL DISCLAIMERADVISORY BOARDFINANCIALSDIABETIC NEPHROPATHYSEDAR XORTX Therapeutics Inc. is a biopharmaceutical company with three products in clinical development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-221 for Type 2 Diabetic Nephropathy (T2DN). RECENT PRESS RELEASES Advancing Partner and Investor Outreach Activities CALGARY, Alberta, March 01, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces its participation in the WuXI Healthcare Forum to be held virtually March 15-18,

CORONAVIRUS

The Company is actively reviewing current studies characterizing the outbreak of COVID-19. The company believes that these published reports may clearly illustrate that acute kidney injury and acute pulmonary injury are key factors in the most serious cases of COVID-19 hospitalization and death. XORTX ANNOUNCES PRIVATE PLACEMENT NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. CALGARY, Alberta, Jan. 07, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces a non-brokered private

MANAGEMENT TEAM

Dr. Allen W. Davidoff, phd CEO Dr. Allen Davidoff (15 years drug development experience) is the founder and CEO of XORTX. Allen has a broad range of clinical and regulatory experience and senior management experience in pharmaceutical R&D including two investigational new drug (“IND”) applications or supplemental IND’s, two phase I studies (four of which were multi-country), seven

phase

XORTX ANNOUNCES APPOINTMENT OF CFO XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com

ADVISORY BOARD

XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com DIABETIC NEPHROPATHY Diabetes is prevalent worldwide and represents and EPIDEMIC in the US: According to the CDC, diabetes affected 11.3% (~25.6 Million) of the U.S. population age 20 or older in 2010, with about 1.9 m REDEFINING HOW KIDNEY DISEASE IS TREATED Our multi-tiered patent portfolio is composed of grantedpatents and patent applications that claim the “use of uric acid lowering agents” for the treatment of hypertension, insulin resistance and diabetic nephropathy (DN) (granted) and acute injury due to XORTXABOUTPIPELINESTRATEGIC PARTNERSHIPSINVESTORSCONTACTCORONAVIRUS XORTX Therapeutics Inc. is a biopharmaceutical company with three products in clinical development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-221, under a letter of intent to establish a co-development program with Teijin Pharma Limited, for Type 2 Diabetic

Nephropathy (T2DN).

PIPELINE – XORTXUPCOMING EVENTSLEGAL DISCLAIMERADVISORY BOARDFINANCIALSDIABETIC NEPHROPATHYSEDAR XORTX Therapeutics Inc. is a biopharmaceutical company with three products in clinical development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-221 for Type 2 Diabetic Nephropathy (T2DN). RECENT PRESS RELEASES Advancing Partner and Investor Outreach Activities CALGARY, Alberta, March 01, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces its participation in the WuXI Healthcare Forum to be held virtually March 15-18,

CORONAVIRUS

The Company is actively reviewing current studies characterizing the outbreak of COVID-19. The company believes that these published reports may clearly illustrate that acute kidney injury and acute pulmonary injury are key factors in the most serious cases of COVID-19 hospitalization and death. XORTX ANNOUNCES PRIVATE PLACEMENT NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. CALGARY, Alberta, Jan. 07, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces a non-brokered private

MANAGEMENT TEAM

Dr. Allen W. Davidoff, phd CEO Dr. Allen Davidoff (15 years drug development experience) is the founder and CEO of XORTX. Allen has a broad range of clinical and regulatory experience and senior management experience in pharmaceutical R&D including two investigational new drug (“IND”) applications or supplemental IND’s, two phase I studies (four of which were multi-country), seven

phase

XORTX ANNOUNCES APPOINTMENT OF CFO XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com

ADVISORY BOARD

XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com DIABETIC NEPHROPATHY Diabetes is prevalent worldwide and represents and EPIDEMIC in the US: According to the CDC, diabetes affected 11.3% (~25.6 Million) of the U.S. population age 20 or older in 2010, with about 1.9 m REDEFINING HOW KIDNEY DISEASE IS TREATED Our multi-tiered patent portfolio is composed of grantedpatents and patent applications that claim the “use of uric acid lowering agents” for the treatment of hypertension, insulin resistance and diabetic nephropathy (DN) (granted) and acute injury due to

INVESTORS – XORTX

XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com

ABOUT US – XORTX

XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com XORTX WELCOMES NEW MEMBER TO BOARD OF DIRECTORS XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com

CORONAVIRUS

The Company is actively reviewing current studies characterizing the outbreak of COVID-19. The company believes that these published reports may clearly illustrate that acute kidney injury and acute pulmonary injury are key factors in the most serious cases of COVID-19 hospitalization and death. XORTX ANNOUNCES PRIVATE PLACEMENT NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. CALGARY, Alberta, Jan. 07, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces a XORTX CLOSES OVER SUBSCRIBED PRIVATE PLACEMENT CALGARY, Alberta, Feb. 10, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that it has closed the over-subscribed private placement, initially announced on January 7, 2021, for total gross proceeds of STRATEGIC PARTNERSHIPS Strategic partnerships are an integral part of our corporate strategy. XORTX Therapeutics is working with development and commercialization partners in garnering new approvals, launching products and developing products that meet the needs of both patients and physicians.

BOARD OF DIRECTORS

XORTX Therapeutics Inc. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727 info@xortx.com DIABETIC NEPHROPATHY Diabetes is prevalent worldwide and represents and EPIDEMIC in the US: According to the CDC, diabetes affected 11.3% (~25.6 Million) of the U.S. population age 20 or older in 2010, with about 1.9 m AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a common life-threatening genetic diseases, affecting many individuals in all parts of the world. ADPKD is a progressive kidney and cardiovas

Skip to content

XRX.CSE: $0.21 __

__

* About

* Management Team

* Board of Directors

* Advisory Board

* Pipeline

* Coronavirus – COVID-19 Program * Autosomal Dominant Polycystic Kidney Disease * Diabetic Nephropathy * Strategic Partnerships

* Investors

* Press Releases

* Financials

* SEDAR

* Transfer Agent

* Upcoming Events

* Contact

__ Site Search

Search for:

XORTX Therapeutics Inc. is a biopharmaceutical company with three products in clinical development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-221, under a letter of intent to establish a co-development program with Teijin Pharma Limited, for Type 2 Diabetic Nephropathy (T2DN). The Company has intellectual property rights and established proof of concept through independent clinical studies. XORTX is working to advance its clinical development stage products that target xanthine oxidase to inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future of patients.

PRESS RELEASES

XORTX WELCOMES NEW MEMBER TO BOARD OF DIRECTORS May 13, 2021 07:00 ET | Source: XORTX Therapeutics Inc. XORTX Therapeutics Inc. Calgary, Alberta, CANADA CALGARY, Alberta, May 13, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biotechnology company focused on developing innovative therapies to treat progressive kidney disease, is pleased ...

Read More

RECEIVE PRESS RELEASES BY EMAIL Please enable the javascript to submit this form XORTX THERAPEUTICS INC. 4000, 421 7th Avenue SW Calgary, Alberta T2P 4K9 Ph: +1 (403) 455-7727

info@xortx.com

Theme by Colorlib Powered by WordPress

__